Iovance prices $150M public offering of 20M shares at $7.50; underwriter option for 3M more

IOVANCE BIOTHERAPEUTICS, INC.

Priced 20M shares at $7.50/share for gross proceeds of $150M; net proceeds ~$140.2M.
Underwriters granted 30-day option for up to 3M additional shares; total offering up to 23M shares.
Proceeds to fund lifileucel commercial launch prep, manufacturing facility, and clinical programs.
Offering led by Goldman Sachs & Co. LLC and Jefferies LLC; expected to close July 13, 2023.
Executive officers and directors entered 90-day lock-up agreements on stock sales.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.99

IOVANCE BIOTHERAPEUTICS, INC. entered into Underwriting Agreement with Goldman Sachs & Co. LLC and Jefferies LLC valued at up to 23,000,000 shares of common stock at $7.50 per share (effective 2023-07-10).

Action: entry
Agreement: underwriting
Counterparty: Goldman Sachs & Co. LLC and Jefferies LLC
Value: up to 23,000,000 shares of common stock at $7.50 per share
Effective: 2023-07-10

Exact text from the filing

On July 10, 2023, Iovance Biotherapeutics, Inc. (the “Company”) entered in an underwriting agreement (the “Underwriting Agreement”) with Goldman Sachs & Co. LLC and Jefferies LLC (collectively, the “Underwriters”), pursuant to which the Company agreed to issue and sell up to 23,000,000 shares of common stock (the “Shares”), which includes 3,000,000 shares (the “Optional Shares”) that may be sold pursuant to a 30-day option to purchase additional shares granted to the Underwriters (the “Offering”).

View on SEC.gov

281 material agreements filed in the last 30 days. Browse all material agreements →

IOVANCE BIOTHERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001104659-23-080013

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.